Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine.
Linda A Parke, Page Burton, Robert V Mcdonald, Joseph A. Kim, Shepard Siegel
Progress in neuro-psychopharmacology & biological psychiatry February 1, 2002 DOI: 10.1016/s0278-5846(01)00268-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Controlled experiment Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | Ibogaine |
| Topics | Addiction Ibogaine |
| Keywords | Compound Acute opioid withdrawal Physical symptoms Motivational aspects Discomfort of withdrawal Addiction treatment Lessen Reduced signs Overcoming opioid dependence Potential to alleviate Distress reduction |
| Citations | 17 |
| Key findings | Ibogaine-treated rats showed weaker aversion to a withdrawal-paired chamber and fewer somatic withdrawal reactions than saline-treated rats after naloxone-precipitated withdrawal from two morphine treatments. |
Abstract
It has been reported that ibogaine interferes with somatic withdrawal reactions in rats chronically treated with morphine. The present experiments demonstrated that ibogaine also interferes with motivational withdrawal reactions and somatic withdrawal reactions in rats treated with morphine on only two occasions. On each of two conditioning trials, naloxone was administered 24 h following an injection of morphine. Four hours prior to each naloxone administration, rats were injected with either ibogaine or saline. In two experiments, ibogaine interfered with naloxone-precipitated withdrawal. In Experiment 1, ibogaine-treated rats displayed a weaker aversion to the withdrawal-paired chamber, and in Experiment 2, ibogaine-treated rats displayed fewer somatic withdrawal reactions than did saline treated rats.